**Axsome Therapeutics Reports Strong Revenue Growth, Advances Pipeline**
Axsome Therapeutics, Inc., a biopharmaceutical company focused on central nervous system (CNS) conditions, announced its financial results for the year ended December 31, 2025, showcasing significant revenue growth driven by its commercial product portfolio. The company reported total revenues of $638.5 million, a 66% increase compared to $385.7 million in 2024. This growth was primarily attributed to increased sales of AUVELITY, a treatment for major depressive disorder (MDD), and SUNOSI, a treatment for excessive daytime sleepiness (EDS), as well as the launch of SYMBRAVO, a migraine treatment, in June 2025, which contributed $6.6 million in revenue. Despite the revenue growth, Axsome reported a net loss of $183.2 million, compared to a net loss of $287.2 million in the previous year.
The company's strategic focus remains on developing and commercializing innovative therapies for CNS disorders. A key development in 2025 was the FDA's acceptance of the supplemental New Drug Application (sNDA) for AXS-05 for the treatment of Alzheimer's disease (AD) agitation, granting it Priority Review with a PDUFA target action date of April 30, 2026. Additionally, solriamfetol is currently in Phase 3 clinical development for the treatment of attention deficit hyperactivity disorder (ADHD), MDD with EDS symptoms, binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD). In November 2025, Axsome acquired Baergic Bio, Inc., gaining global rights to AXS-17 (formerly AZD7325) for the potential treatment of epilepsy, for an upfront payment of $2.3 million, with potential milestone payments and royalties.
Key operational developments included the commercial launch of SYMBRAVO in the U.S. in June 2025, expanding Axsome's presence in the migraine treatment market. The company also received formal pre-NDA meeting minutes from the FDA supporting an NDA submission for AXS-12 for the treatment of cataplexy in narcolepsy. In November 2025, Axsome acquired the global rights to deuterium-stabilized S-bupropion from DeuteRx, LLC, a privately held biopharmaceutical company, for contingent development, regulatory and sales-based milestones of up to $523 million and a tiered low single-digit royalty on potential global net sales. As of February 16, 2026, Axsome had 925 full-time employees.
Axsome's outlook includes continued investment in its commercial infrastructure and pipeline development. The company anticipates research and development expenses to stabilize in the near term as certain development programs near completion while new development programs are initiated. Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan. However, the company acknowledges the need for potential future financing to support its ongoing activities and strategic objectives.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel oral therapies for central nervous system (CNS) disorders. Its portfolio includes FDA-approved products for major depressive disorder, excessive daytime sleepiness, and acute migraine treatment, alongside late-stage candidates for Alzheimer’s agitation, narcolepsy, fibromyalgia, and other CNS conditions. Axsome leverages proprietary formulation technologies and targets underserved CNS markets with high unmet medical needs, primarily serving patients and healthcare providers in the U.S.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.